Solutions

Clinical solutions

Blended Solutions Cardiac Safety Solutions Clinical & Scientific Operations Decentralised Clinical Trials Early Clinical Laboratories Medical Imaging Site & Patient Solutions Strategic Solutions

Consulting & Commercial

Asset Development Consulting Commercial Positioning Language Services Outcome Measures Real World Intelligence Regulatory Affairs Symphony Health data

Case studies
Reducing time to market, delivering on quality, providing deep therapeutic expertise and enhancing R&D ROI.

Technologies
Technology solutions from early phase through to post-marketing.
Sectors

Sectors

ICON provides its full range of clinical, consulting and commercial services across several industry sectors.

Read more

Biotech Government and Public Health Medical Device Pharmaceuticals

Biotech
Developing transformative therapies requires a flexible approach.

ICON and You
Partners making a difference.
Therapeutics

Therapeutics

Cardiovascular Central Nervous System Endocrine & Metabolic Disorders Hepatology Infectious Diseases Internal Medicine & Immunology Oncology

Cross-therapeutics

Biosimilars Cell and Gene Therapies Medical Device Pediatrics Rare & Orphan Diseases Vaccines Women's Health

Obesity
A focus on combination therapies requires appropriate obesity-specific trial designs, long-term follow-up studies and diverse patient recruitment.

Therapeutics insights
ICON's therapeutic experts contribute regularly to industry publications and the creation of thought leadership content. Read more.
Insights

Insights

Digital Disruption Patient Centricity Regulatory Intelligence Therapeutics insights Transforming Trials Value Based Healthcare Blog Videos Webinar Channel

Building a comparative evidence base using network meta-analysis
Methods, implementation and reporting

Download 2025 Global and China biotech sector survey reports
Two new reports of surveys of 260+ Global and China biotech leaders have just been released

From bottlenecks to breakthroughs
Human-centred strategies for faster study starts
News & Events

News & Events

ICON regularly contributes thought leadership to industry media publications and conferences, and has been recognised as one of the world’s leading Contract Research Organisations through a number of high-profile industry awards.

Read more

Press releases In the News Mediakit Awards Events Webinars Social media

ICH GCP E6(R3): Preparing for global implementation, assessing the impact, risk and requirements of the change
Watch the webinar.

Riding the data wave: How pharma can navigate disruptions in open claims
Watch the webinar.
About ICON

About ICON

Company history ICON at a glance ICON in Asia Pacific ICON in Latin America Leadership Quality

ICON for

Patients Volunteers Investigators Jobs & Careers Investors Suppliers

Sustainability, charity, inclusion and belonging
ICON Cares is our commitment to making a positive impact on our people, environment and our community.

ICON at a glance
Delivering successful outcomes across the clinical development lifecycle.

Careers
Investors
Contact
日本語
简体中文

Home
News & Events
Social media

Social media

Showing 745 - 756 of 955 results for "*"

Drop by booth #69 at #OCTNewEngland2025, 15– 16 October. Meet the ICON experts to explore new solutions to common issues within clinical trials. Learn how we can simplify processes to help you meet critical milestones, o...

3 Oct

1 1

ICON Plc

Drop by booth \#69 at #OCTNewEngland2025, 15– 16 October. Meet the ICON experts to explore new solutions to common issues within clinical trials. Learn how we can simplify processes to help you meet critical milestones, ...

3 Oct

ICON Plc

Despite increased female participation, most Clinical Outcome Assessments (COAs) are still designed around male biology. A recent analysis found that less than 10% of COAs were developed with female-specific populations....

3 Oct

ICON Plc

We are proud to share that our colleagues in Sofia took part in the Race for the Cure® on 28 September. Race for the Cure is Europe’s largest sporting event for women’s health, bringing together communities to support b...

3 Oct

ICON Plc

Big news in clinical research! The updated ICH GCP E6(R3) guideline is here and it’s changing how trials are designed and run. Our article in PharmaTimes explains why a detailed impact assessment is the first step to sta...

3 Oct

ICON Plc

ICH GCP E6(R3) is here. Are you ready? The new guideline introduces sweeping changes to clinical trial operations. In the latest issue of PharmaTimes, ICON’s own Joanne Perry explores why a comprehensive impact assessm...

3 Oct

ICON Plc

Biomarkers are redefining clinical trial success in neurodegenerative diseases. Join us for a focused webinar on how imaging, wet, genetic, and digital biomarkers are improving trial accuracy, patient selection, and end...

2 Oct

ICON Plc

Join leading experts in #neuroscience and clinical development as they discuss how #biomarkers are transforming trials in Alzheimer’s, Parkinson’s, and related neurodegenerative diseases. This session will cover: - Inte...

2 Oct

ICON Plc

We’re looking forward to participating in and hosting C-Path's annual eCOA Consortium EU meeting on October 8–9 at ICON’s Dublin office. This meeting brings together leading eCOA experts to address key industry challen...

LabView360 is ICON’s new digital requisitioning application that streamlines end-to-end sample management—eliminating paper requisition forms, reducing errors, and saving valuable time for sites and sponsors. With digi...

2 Oct